ArticleDiscover oncology2025
Prevalence of GLUT1 overexpression in human cancers a systematic review and meta analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Histone deacetylases in cancer metabolic reprogramming.Experimental & molecular medicine · 2026Review
- Shared Major Metabolic Pathways and Potential Targeted Therapies in Malignancies and Systemic Lupus Erythematosus.Biomolecules · 2026Review
- Metabolic Marker GLUT1 in Salivary Gland Cancers: Quantification and Effect-Size Estimation.Biomedicines · 2026Article
- Development of Glycoconjugated MAGL Inhibitors with Glucose-Dependent Antiproliferative Activity.International journal of molecular sciences · 2026Article
- Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026Review
- FOXD1, a hypoxia-related gene, accelerates prostate cancer cell growth by increasing glycolysis under hypoxia conditions.BMC biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance of glucose transporter 1 (GLUT1) expression in cancers remains controversial due to inconsistent findings. This meta-analysis systematically evaluates the association between GLUT1 overexpression and its prevalence in cancer tissues, highlighting its potential role as a diagnostic biomarker.
methodsA comprehensive search of MEDLINE and the Cochrane Library was performed up to May 30, 2024, to identify observational studies and RCTs examining the association of GLUT1 expression with its prevalence in cancer tissues. Data were analyzed using random-effects models, and results were presented as Risk Ratios (RRs) with 95% confidence intervals (CIs). Subgroup analyses were performed based on cancer types and geographical locations. This meta-analysis focused on the diagnostic significance of GLUT1 expression in distinguishing cancer tissues from normal tissues. Publication bias and sensitivity analyses were assessed.
resultsSeventeen studies with 1,795 patients were included. GLUT1 overexpression was significantly associated with its prevalence in cancer tissues compared to normal tissues (RR = 5.57, 95% CI = 3.42-9.09, P < 0.001). Subgroup analysis showed the highest prevalence in urological cancers (RR = 20.56, 95% CI = 10.85-38.93), followed by head and neck cancers (RR = 18.00, 95% CI = 2.66-121.63), and gynecological cancers (RR = 10.55, 95% CI = 2.06-54.00). Geographical analysis indicated a stronger association in Europe (RR = 24.18, 95% CI = 13.37-43.73) than in East Asia (RR = 6.16, 95% CI = 2.69-14.15) and North America (RR = 1.90, 95% CI = 1.32-2.73). This analysis evaluates the diagnostic significance of GLUT1 expression in cancer tissues. Evidence of publication bias was detected based on Egger's test (z = 4.667, p < 0.001), suggesting funnel plot asymmetry.
conclusionGLUT1 overexpression is associated with its high prevalence in cancer tissues, particularly in urological and head and neck cancers. These findings suggest that GLUT1 may serve as a potential diagnostic biomarker in oncology. However, this study does not evaluate survival outcomes (such as overall survival or progression-free survival), and further research is needed to determine its diagnostic significance and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.